Aclaris Therapeutics, Inc. (0H8T.L) LSE

2.10

+0.1243(+6.31%)

Updated at September 08 06:36PM

Currency In USD

Valuation

Market Cap185.51M
Enterprise Value163.54M
P/E Ratio-1.89
PEG Ratio-1.32
Price/Sales Ratio13.42
Price/Book Ratio1.94
Enterprise/Revenue12.05
Enterprise/EBITDA-3.59

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-8.02
Operating Margin-8.73

Management Effectiveness

Return On Assets-0.71
Return On Equity-0.96

Income Statement

Revenue18.72M
Revenue/Share0.14
Gross Profit3.46M
EBITDA-131.26M
Net Income-132.07M
Diluted EPS-1.71

Balance Sheet

Total Cash99.81M
Total Cash/Share0.81
Total Debt2.37M
Total Debt/Equity0.02
Current Ratio3.88
Book Value Per Share1.07

Price History

52-Week Change74.58
52-Week High10.87
52-Week Low0.61
Moving Average 50 Days1.2
Moving Average 200 Days4.31

Statistics

Average Volume12,279
Shares Outstanding103M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A